8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

DEFA14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

DEF 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

bioAffinity Technologies' noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient's lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation. "We believe that this patient's experience demonstrates the high added value that CyPath® Lung brings to the diagnostic pathway. Multiple procedures and diagnostic tools were incon

New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian

One third of world's smokers live in China, which has highest rate of lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to th

bioAffinity Technologies' noninvasive sputum test revealed early-stage lung cancer when other diagnostic options were contraindicated bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in a patient whose PET imaging and risk model probability indicated a low risk of malignancy. "CyPath® Lung gave us the critical data point we were missing. This patient had all the red flags – heavy tobacco use, COPD and a suspicious nodule – but imaging and ri

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company's recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting tw

Company research targets topical application for treatment of skin cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of "The Drive for Early Detection," a case study detailing how bioAffinity Technologies utilizes support from Cardinal Health™ OptiFreight® Logistics to help meet demand for CyPath® Lung, a noninvasive test for detection of early stage lung cancer. "Our innovative, accurate diagnostic for lung cancer relies on dependable, on-time delivery of viable sputum samples to our laboratory for processing and providing reliable results to patients and their physicians," bioAffinity President and CEO Maria Zannes said. "CyPa

Simultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill Cancer Company Research Targets Topical Application for Treatment of Skin Cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The patent, "Compositions and Methods for Treating Cancer," (Patent No. 12,305,171) provides for use of the novel therapeutic approach with cancers of the lung

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath® Lung, the Company's noninvasive test to detect early-stage lung cancer. Reported accelerating growth of 350% in CyPath® Lung tests ordered and processed in Q1 2024 as

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. "Dr. Platt's impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115775728/en/A partnership to improve lung cancer screening. (Graphic: Business Wire) "The Power of Three" campaign emphasizes the importance of joining forces in the fight against lung cancer by supporting local programs like the Quality Improvement Program to Increase Lu

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America's therapeutic solutions division. Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. "We are delighted

Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath® Lung brand bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies' Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector. CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learnin

SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloombe

Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity's Board of Directors Conference Call at 4:30 p.m. Eastern time Today bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The laboratory assets are being acquire

Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions. Event:       bioAffinity Technologies Fourth Quarter 2022 Financial Results Date:       Monday, April 3, 2023 Time:       9:00 a.m. EDT Toll Free:       1-877-270-2148 International:       1-412-902-6510 Webcast:       Webcast link A replay o